Table 1.
Randomized control trials since 2014 assessing bevacizumab use in newly diagnosed glioblastoma.
| First Author (Year) | Level of Study | n | Median Age (Years) | Duration of Follow-up (Months) | Treatment | Control | Prior Treatment | |
|---|---|---|---|---|---|---|---|---|
| 1 | Balana [14] (2016) | I | Tx: 49 Control: 53 | Tx: 62.9 Control: 62.0 | >18.0 | BEV + TMZ | TMZ | Biopsy only |
| 2 | Carlson [15] (2015) | I | Tx: 30 Control: 26 | Tx: 56.5 Control: 60.5 | Tx: 14.7 Control: 13.9 | BEV + Hypo-IMRT + TMZ | Hypo-IMRT + TMZ | Biopsy/Sx |
| 3 | Chauffert [16] (2014) | I | Tx: 60 Control: 60 | Tx: 60.2 Control: 60.9 | – | BEV + IRI + RT + TMZ | RT + TMZ | Biopsy only |
| 4 | Chinot [9] (2014) | I | Tx: 458 Control: 463 | Tx: 57.0 Control: 56.0 | Tx: 14.4 Control: 13.7 | BEV + RT + TMZ | PLA + RT + TMZ | Biopsy/Sx |
| 5 | Gilbert [10] (2014) | I | Tx: 312 Control: 309 | Tx: 59.0 Control: 57.0 | 20.5 | BEV + RT + TMZ | PLA + RT + TMZ | Biopsy/Sx |
| 6 | Herrlinger [17] (2016) | I | Tx: 116 Control: 54 | Tx and Control: 56.0 | – | BEV + IRI + RT | RT + TMZ | Biopsy/Sx |
| 7 | Wirsching [18] (2018) | I | Tx: 50 Control: 25 | Tx: 70 Control: 70 | – | BEV + Hypo-RT | Hypo-RT | Sx, steroids |
Abbreviations: Tx, treatment; BEV, bevacizumab; TMZ, temozolomide; RT, radiotherapy; Sx, resective surgery; Hypo-IMRT, hypofractionated-intensity modulated radiotherapy; IRI, irinotecan; PLA, placebo; hypo-RT, hypofractionated radiotherapy. All studies administered BEV intravenously at 10 mg/kg every two weeks, starting at varying time points within treatment plan.